e-therapeutics plc
("e-therapeutics" or
the "Company")
Total Voting
Rights
London, UK,
31 January 2024 -
e-therapeutics plc (AIM: ETX), a company integrating computational
power and biological data to discover life-transforming RNAi
medicines, announces that in accordance with the Financial Conduct
Authority's Disclosure and Transparency Rules, the Company has
584,335,487 ordinary shares of 0.1 pence each in issue, none of
which are held in treasury. Therefore, the total number of voting
rights in the Company is 584,335,487.
The above figure of 584,335,487 may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company.
Enquiries:
|
e-therapeutics
plc
|
|
|
Ali Mortazavi, CEO
Timothy Bretherton, CFO
|
Tel: +44 (0)20 4551 8888
www.etherapeutics.co.uk
|
|
SP Angel Corporate Finance
LLP
|
Tel: +44(0)20 3470 0470
|
|
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
|
|
About e-therapeutics plc
e-therapeutics plc ("ETX")
integrates computational power and biology information to discover
life-transforming RNAi medicines. The Company's technology uses
computation to capture and model human biology, identify novel
targets, and develop RNAi medicines against those targets that can
be rapidly progressed to the clinic.
ETX's proprietary HepNet™ platform
enables the generation and analysis of biological network models,
providing a novel and mechanistic approach to drug discovery. This
approach explicitly considers the true complexity of biology to
make more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most
comprehensive and integrated hepatocyte-centric data
resource. The Company generates, prioritises, and tests
millions of hypotheses in silico to identify better therapeutic
targets with higher confidence.
GalOmic™, ETX's proprietary RNAi
platform, enables targeted delivery to hepatocytes in the liver and
the specific silencing of novel disease-associated genes,
identified by HepNet™. The focus on hepatocytes offers the
opportunity to tackle a wide variety of diseases. The liver
is a highly metabolically active organ which performs a key role in
many biological processes and vital functions crucial for human
health. ETX's GalOmic™ constructs have demonstrated compelling in
vivo performance in terms of depth of gene silencing and duration
of action.
The Company is progressing a
pipeline of first-in-class RNAi candidates across a variety of
therapeutic areas with high unmet need, including preclinical
programs in cardiometabolic and metabolic diseases, haemophilia,
and other undisclosed indications. ETX has also partnered with
biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach
across a diverse range of drug discovery projects.
The Company is based in London, UK
and listed on the Alternative Investment Market of the London Stock
Exchange ("AIM"), with ticker symbol ETX.
